Session Title: Quick Fire Free Paper Session 03
Session Date/Time: Sunday 29/09/2013 | 08:30-09:30
Paper Time: 09:20
Venue: Hall C (Level 1)
First Author: M.Ondrejkova SLOVAKIA
Co Author(s): M. Gajdo?ov Z. Pohankov
Effect of anti-VEGF in patients with large submacular haemorrhage secondary to CNV in ARMD.
OFTAL s.r.o, Specialized Ophtalmology Hospital, Zvolen, Slovakia
17 eyes of 17 patients , mean age 81,5 years (65-89years), with large submacular haemorrhage were treated with anti VEGF (ranibizumab, pegaptanib, bevacizumab) in accordance with current practice. Follow up was at monthly intervals. The mean follow up time was 22,2 months (12-42 months). Size of the haemorrhage, best corrected visual acuity ( BCVA) and central retinal thickness (CRT) at baseline and during follow up were analysed.
Baseline BCVA was 0,13 (0,3 and less), 28,65 letters in ETDRS letters score . After 12 months the BCVA was 0,2 (0,8 and less ), 36 letters. The mean change was + 7,35 letters. Over the course of the treatment 12 (70,6%) of 17 eyes were stable or improved. 6 (35,3%) eyes had 2 and more lines improvement. The mean number of injections was 4,9. The mean CRT decreased from 577 um at the baseline to 370 um after 12 months . The mean CRT reduction was - 207 um. No local or systemic side effects of this therapy were recorded.
Haemorrhagic CNV in ARMD could be succesfully treated with anti VEGF monotherapy with good functional and anatomical results in most of the patients, suggesting that the displacement of the submacular haemorrhage may not be necessary.